Director, Talent Acquisition
Crescent Biopharma
Director, Talent Acquisition
Crescent Biopharma
Clinical-stage biotech developing solid-tumor therapies
We are seeking an experienced Director, Talent Acquisition to implement and execute recruitment strategies and programs to attract best in class talent. In partnership with the HR team, you will lead and elevate our end-to-end recruiting function during a pivotal period of growth.
You will create and manage talent pipelines, coordinate recruiting initiatives, and leverage relationships with third party search partners. Serve as a strategic partner to hiring managers to drive talent acquisition strategies that attract best-in-class talent to Crescent. This is a high-impact, highly visible role for a seasoned talent leader who thrives in a fast-moving biotech environment and is passionate about building the team behind a transformational oncology mission.
Please note:
Crescent Biopharma is an Equal Opportunity Employer. We are committed to fostering a diverse, inclusive, and equitable workplace where all individuals are valued and respected. Employment decisions are based on qualifications, merit, and business needs, without regard to race, color, religion, gender, sexual orientation, national origin, disability, veteran status, or any other protected status.
Please note, Crescent does not accept unsolicited resumes from external agencies or recruiters. Submission of a resume without a prior written agreement does not create any express or implied contract between Crescent and the agency. Crescent will not pay any fees related to unsolicited resumes.
#LI-CBIO
Clinical-stage biotech developing solid-tumor therapies
Crescent Biopharma develops oncology therapies for solid tumors, led by CR-001, a tetravalent bispecific antibody that blocks PD-1 and VEGF to boost anti-tumor immunity while inhibiting tumor blood vessel growth. CR-001 sits in a global Phase 1/2 ASCEND trial, and the pipeline also includes CR-002, an anti-PD-L1 antibody-drug conjugate, and CR-003, an ITGB6-targeted ADC. The company differentiates itself by combining immune checkpoint blockade with VEGF inhibition and other targeted modalities to build an immuno-oncology backbone for solid tumors, supported by strategic partnerships and substantial private placements. Crescent’s goal is to advance multi-agent regimens toward regulatory approval and commercial development for patients with solid tumors.
Explore more opportunities at Crescent Biopharma